Data move Endologix' AAA (abdominal aortic aneurysms) graft closer to France
This article was originally published in Clinica
Endologix has moved a step closer to commercialising in France its PowerLink endoluminal stent graft (ELG) for treating of abdominal aortic aneurysms (AAAs), following positive trial results. In addition, says the company, two-year data from a separate trial are now available to support the product as a treatment for the condition.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.